SCHEMBL12412346

SCHEMBL12412346

[C-]#[N+]c1cc2c(Oc3ccc(NC(=O)NC4CC4)c(F)c3)ccnc2cc1OCCCN1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.55
MET P08581 4/20 0.55
KIT P10721 3/20 0.55
AXL P30530 3/20 0.55
EGFR P00533 2/20 0.55
RET P07949 2/20 0.55
IGF1R P08069 1/20 0.55
SRC P12931 1/20 0.55
MST1R Q04912 1/20 0.55
FLT1 P17948 11/20 0.54
FLT4 P35916 11/20 0.54
FGFR4 P22455 3/20 0.53
PDGFRA P16234 2/20 0.46
FGFR2 P21802 2/20 0.46
RIPK2 O43353 1/20 0.46
ERN1 O75460 1/20 0.46
STK10 O94804 1/20 0.46
MAP3K6 O95382 1/20 0.46
ABL1 P00519 1/20 0.46
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12412415 0.92 FLT1 (0.65) KDRKITRETFLT1FLT4
SCHEMBL12412086 0.91 FLT1 (0.66) KDRKITRETFLT1FLT4
SCHEMBL12412255 0.88 FGFR4 (0.52) KDRMETKITAXLEGFR
SCHEMBL12412257 0.88 KDR (0.54) KDRMETKITAXLEGFR
SCHEMBL12412252 0.88 FGFR4 (0.52) KDRMETKITAXLEGFR
SCHEMBL1894739 0.87 KDR (0.55) KDRMETKITAXLEGFR
SCHEMBL12411355 0.87 FGFR4 (0.57) KDRMETKITAXLRET
SCHEMBL12412260 0.87 KDR (0.55) KDRMETKITAXLEGFR
SCHEMBL14540600 0.86 KDR (0.56) KDRMETKITAXLEGFR
SCHEMBL12411267 0.86 KDR (0.52) KDRMETKITAXLEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives GNG2, GCG, FRG1 KDR 2687/4885MET 1810/4885KIT 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.